| Melanie Morris, | |
|
1717 6th Ave S, Birmingham, AL 35233-1801 | |
| (800) 822-8816 | |
| Not Available |
| Full Name | Melanie Morris |
|---|---|
| Gender | Female |
| Speciality | General Surgery |
| Experience | 21 Years |
| Location | 1717 6th Ave S, Birmingham, Alabama |
| Accepts Medicare Assignments | Yes. She accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1003011859 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 208600000X | Surgery | 30315 (Alabama) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| University Of Alabama Hospital | Birmingham, AL | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| University Of Alabama Health Services Foundation, Pc | 1951213107 | 2344 |
News Archive
Advanced Cell Technology, Inc., a leader in the field of regenerative medicine, today announced treatment of the fourth patient, the first in the second patient cohort, in its U.S. clinical trial for Stargardt's Macular Dystrophy (SMD).
Takeda Pharmaceutical Company Limited and its wholly-owned subsidiary, Takeda Pharmaceuticals International GmbH, today announced that the European Commission has granted Marketing Authorisation for Entyvio (vedolizumab), a gut-selective humanized monoclonal antibody, and the first and only biologic therapy to be approved simultaneously for the treatment of adults with moderately to severely active ulcerative colitis (UC) and adults with moderately to severely active Crohn's disease (CD) who have had an inadequate response with, lost response to, or were intolerant to either conventional therapy or a tumor necrosis factor-alpha (TNFα) antagonist.
The Down Syndrome Research and Treatment Foundation (DSRTF) announces the identification of a new potential therapeutic strategy to address cognitive decline and improve cognition in Down syndrome. The findings were published in Science Translational Medicine on November 18, 2009 by DSRTF-supported researchers, Drs. Ahmad Salehi, William Mobley, and colleagues at Stanford and UCSD Schools of Medicine.
Oregon Health & Science University Cancer Institute researchers have found a new, experimental drug candidate it to be effective against a highly resistant mutation in chronic myeloid leukemia (CML).
COVID-19 cases were climbing at Michigan's McLaren Flint hospital. So Roger Liddell, 64, who procured supplies for the hospital, asked for an N95 respirator for his own protection, since his work brought him into the same room as COVID-positive patients.
› Verified 4 days ago
| Entity Name | University Of Alabama Health Services Foundation, Pc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1093768723 PECOS PAC ID: 1951213107 Enrollment ID: O20031105000261 |
News Archive
Advanced Cell Technology, Inc., a leader in the field of regenerative medicine, today announced treatment of the fourth patient, the first in the second patient cohort, in its U.S. clinical trial for Stargardt's Macular Dystrophy (SMD).
Takeda Pharmaceutical Company Limited and its wholly-owned subsidiary, Takeda Pharmaceuticals International GmbH, today announced that the European Commission has granted Marketing Authorisation for Entyvio (vedolizumab), a gut-selective humanized monoclonal antibody, and the first and only biologic therapy to be approved simultaneously for the treatment of adults with moderately to severely active ulcerative colitis (UC) and adults with moderately to severely active Crohn's disease (CD) who have had an inadequate response with, lost response to, or were intolerant to either conventional therapy or a tumor necrosis factor-alpha (TNFα) antagonist.
The Down Syndrome Research and Treatment Foundation (DSRTF) announces the identification of a new potential therapeutic strategy to address cognitive decline and improve cognition in Down syndrome. The findings were published in Science Translational Medicine on November 18, 2009 by DSRTF-supported researchers, Drs. Ahmad Salehi, William Mobley, and colleagues at Stanford and UCSD Schools of Medicine.
Oregon Health & Science University Cancer Institute researchers have found a new, experimental drug candidate it to be effective against a highly resistant mutation in chronic myeloid leukemia (CML).
COVID-19 cases were climbing at Michigan's McLaren Flint hospital. So Roger Liddell, 64, who procured supplies for the hospital, asked for an N95 respirator for his own protection, since his work brought him into the same room as COVID-positive patients.
› Verified 4 days ago
| Entity Name | The Russell Hospital Corporation |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1417252537 PECOS PAC ID: 6406754431 Enrollment ID: O20110307000502 |
News Archive
Advanced Cell Technology, Inc., a leader in the field of regenerative medicine, today announced treatment of the fourth patient, the first in the second patient cohort, in its U.S. clinical trial for Stargardt's Macular Dystrophy (SMD).
Takeda Pharmaceutical Company Limited and its wholly-owned subsidiary, Takeda Pharmaceuticals International GmbH, today announced that the European Commission has granted Marketing Authorisation for Entyvio (vedolizumab), a gut-selective humanized monoclonal antibody, and the first and only biologic therapy to be approved simultaneously for the treatment of adults with moderately to severely active ulcerative colitis (UC) and adults with moderately to severely active Crohn's disease (CD) who have had an inadequate response with, lost response to, or were intolerant to either conventional therapy or a tumor necrosis factor-alpha (TNFα) antagonist.
The Down Syndrome Research and Treatment Foundation (DSRTF) announces the identification of a new potential therapeutic strategy to address cognitive decline and improve cognition in Down syndrome. The findings were published in Science Translational Medicine on November 18, 2009 by DSRTF-supported researchers, Drs. Ahmad Salehi, William Mobley, and colleagues at Stanford and UCSD Schools of Medicine.
Oregon Health & Science University Cancer Institute researchers have found a new, experimental drug candidate it to be effective against a highly resistant mutation in chronic myeloid leukemia (CML).
COVID-19 cases were climbing at Michigan's McLaren Flint hospital. So Roger Liddell, 64, who procured supplies for the hospital, asked for an N95 respirator for his own protection, since his work brought him into the same room as COVID-positive patients.
› Verified 4 days ago
| Entity Name | Lv Stabler Primary Care Llc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1871003533 PECOS PAC ID: 7719246586 Enrollment ID: O20180124002028 |
News Archive
Advanced Cell Technology, Inc., a leader in the field of regenerative medicine, today announced treatment of the fourth patient, the first in the second patient cohort, in its U.S. clinical trial for Stargardt's Macular Dystrophy (SMD).
Takeda Pharmaceutical Company Limited and its wholly-owned subsidiary, Takeda Pharmaceuticals International GmbH, today announced that the European Commission has granted Marketing Authorisation for Entyvio (vedolizumab), a gut-selective humanized monoclonal antibody, and the first and only biologic therapy to be approved simultaneously for the treatment of adults with moderately to severely active ulcerative colitis (UC) and adults with moderately to severely active Crohn's disease (CD) who have had an inadequate response with, lost response to, or were intolerant to either conventional therapy or a tumor necrosis factor-alpha (TNFα) antagonist.
The Down Syndrome Research and Treatment Foundation (DSRTF) announces the identification of a new potential therapeutic strategy to address cognitive decline and improve cognition in Down syndrome. The findings were published in Science Translational Medicine on November 18, 2009 by DSRTF-supported researchers, Drs. Ahmad Salehi, William Mobley, and colleagues at Stanford and UCSD Schools of Medicine.
Oregon Health & Science University Cancer Institute researchers have found a new, experimental drug candidate it to be effective against a highly resistant mutation in chronic myeloid leukemia (CML).
COVID-19 cases were climbing at Michigan's McLaren Flint hospital. So Roger Liddell, 64, who procured supplies for the hospital, asked for an N95 respirator for his own protection, since his work brought him into the same room as COVID-positive patients.
› Verified 4 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Melanie Morris, 1717 6th Ave S, Birmingham, AL 35233-1801 Ph: () - | Melanie Morris, 1717 6th Ave S, Birmingham, AL 35233-1801 Ph: (800) 822-8816 |
News Archive
Advanced Cell Technology, Inc., a leader in the field of regenerative medicine, today announced treatment of the fourth patient, the first in the second patient cohort, in its U.S. clinical trial for Stargardt's Macular Dystrophy (SMD).
Takeda Pharmaceutical Company Limited and its wholly-owned subsidiary, Takeda Pharmaceuticals International GmbH, today announced that the European Commission has granted Marketing Authorisation for Entyvio (vedolizumab), a gut-selective humanized monoclonal antibody, and the first and only biologic therapy to be approved simultaneously for the treatment of adults with moderately to severely active ulcerative colitis (UC) and adults with moderately to severely active Crohn's disease (CD) who have had an inadequate response with, lost response to, or were intolerant to either conventional therapy or a tumor necrosis factor-alpha (TNFα) antagonist.
The Down Syndrome Research and Treatment Foundation (DSRTF) announces the identification of a new potential therapeutic strategy to address cognitive decline and improve cognition in Down syndrome. The findings were published in Science Translational Medicine on November 18, 2009 by DSRTF-supported researchers, Drs. Ahmad Salehi, William Mobley, and colleagues at Stanford and UCSD Schools of Medicine.
Oregon Health & Science University Cancer Institute researchers have found a new, experimental drug candidate it to be effective against a highly resistant mutation in chronic myeloid leukemia (CML).
COVID-19 cases were climbing at Michigan's McLaren Flint hospital. So Roger Liddell, 64, who procured supplies for the hospital, asked for an N95 respirator for his own protection, since his work brought him into the same room as COVID-positive patients.
› Verified 4 days ago
Rebecca Horst, PA Surgery Medicare: Medicare Enrolled Practice Location: 817 Princeton Ave Sw Ste 306, Birmingham, AL 35211 Phone: 205-783-0160 Fax: 205-788-6249 | |
Timothy Lee Christopher, M.D. Surgery Medicare: Accepting Medicare Assignments Practice Location: 3686 Grandview Pkwy Ste 400, Birmingham, AL 35243 Phone: 205-595-8985 Fax: 205-595-8987 | |
Dr. Richard Ira Kirkland, MD Surgery Medicare: Medicare Enrolled Practice Location: 513 Brookwood Blvd, Suite 501, Birmingham, AL 35209 Phone: 205-930-8010 Fax: 205-930-8014 | |
Kyle Stigall, MD Surgery Medicare: Medicare Enrolled Practice Location: 619 19th St S, Birmingham, AL 35233 Phone: 205-934-4011 | |
Jayme Locke, Surgery Medicare: Accepting Medicare Assignments Practice Location: 1717 6th Ave S, Birmingham, AL 35233 Phone: 800-822-8816 | |
Emily Long, MD Surgery Medicare: Medicare Enrolled Practice Location: 50 Medical Park Dr E, Birmingham, AL 35235 Phone: 205-838-3000 |